Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 20, Issue 1, 2010, Pages 97-104

  Lanni, Cristina ^a   Racchi, Marco ^a   Stanga, Serena ^a   Mazzini, Giuliano ^a   Ranzenigo, Alberto ^b   Polotti, Renzo ^b   Memo, Maurizio ^c   Govoni, Stefano ^a   Uberti, Daniela ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b S Orsola Hospital   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

cytofluorimetric approach; mild cognitive impairment; risk factor; unfolded blood p53

Indexed keywords

PROTEIN P53;

AGE DISTRIBUTION; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BLOOD; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE;

EID: 77954505297     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1347     Document Type: Article

References (45)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M(2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117.
2. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, Beyreuther K, Masters CL (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38, 1688-1693.
3. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
4. Chertkow H, Nasreddine Z, Joanette Y, Drolet V, Kirk J, Massoud F, Belleville S, Bergman H (2007) Mild cognitive impairment and cognitive impairment, no dementia: Part A, concept and diagnosis. Alzheimers Dement 3, 266-282. (Pubitemid 47553568)
5. Triebel KL, Martin R, Griffith HR, Marceaux J, Okonkwo OC, Harrell L, Clark D, Brockington J, Bartolucci A, Marson DC (2009) Declining financial capacity in mild cognitive impairment: A 1-year longitudinal study. Neurology 73, 928-934.
6. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246.
7. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
8. Mariani E, Monastero R, Mecocci P (2007) Mild cognitive impairment: a systematic review. J Alzheimers Dis 12, 23-35.
9. Lehrner J, Gufler R, Guttmann G, Maly J, Gleiss A, Auff E, Dal-Bianco P (2005) Annual conversion to alzheimer disease among patients with memory complaints attending an outpatient memory clinic: the influence of amnestic mild cognitive impairment and the predictive value of neuropsychological testing. Wien Klin Wochenschr 117, 629-635.
10. Schmidtke K, Hermeneit S (2008) High rate of conversion to Alzheimer's disease in a cohort of amnestic MCI patients. Int Psychogeriatr 20, 96-108.
11. Palmer K, Wang HX, Backman L, Winblad B, Fratiglioni L (2002) Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project. Am J Psychiatry 159, 436-442.
12. Andersen K, Nybo H, Gaist D, Petersen HC, McGue M, Jeune B, Vaupel JW, Christensen K (2002) Cognitive impairment and mortality among nonagenarians: the Danish 1905 Cohort Survey. Dement Geriatr Cogn Disord 13, 156-163.
13. Bullock AN, Fersht AR (2001) Rescuing the function of mutant p53. Nat Rev Cancer 1, 68-76.
14. Lavin MF, Gueven N (2006) The complexity of p53 stabilization and activation. Cell Death Differ 13, 941-950.
15. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2, 594-604.
16. Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, Proctor MR, Lane DP, Fersht AR (1997) Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A 94, 14338-14342.
17. Bullock AN, Henckel J, Fersht AR (2000) Quantitative analysis of residual folding and DNAbinding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19, 1245-1256.
18. Nikolova PV, Henckel J, Lane DP, Fersht AR (1998) Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A 95, 14675-14680.
19. Wong KB, DeDecker BS, Freund SM, Proctor MR, Bycroft M, Fersht AR (1999) Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci U S A 96, 8438-8442.
20. Ḿeplan C, Mann K, Hainaut P (1999) Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells. J Biol Chem 274, 31663-31670.
21. Ḿeplan C, Richard MJ, Hainaut P (2000) Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 19, 5227-5236.
22. Ḿeplan C, Richard MJ, Hainaut P (2000) Redox signalling and transition metals in the control of the p53 pathway. Biochem Pharmacol 59, 25-33.
23. Wu HH, Sherman M, Yuan Y-C, Momand J (1999) Direct redox modulation of p53: potential sources of redox control and potential outcomes. Gene Therapy Mol Biol 4, 119-132.
24. Lanni C, Racchi M, Mazzini G, Ranzenigo A, Polotti R, Sinforiani E, Olivari L, Barcikowska M, Styczynska M, Kuznicki J, Szybinska A, Govoni S, Memo M, Uberti D (2008) Conformationally altered p53: a novel Alzheimer's disease marker? Mol Psychiatry 13, 641-647.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
26. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31, 545-548.
27. Busse A, Hensel A, Gühne U, Angermeyer MC, Riedel-Heller SG (2006) Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 67, 2176-2185.
28. Lanni C, Racchi M, Uberti D, Mazzini G, Stanga S, Sinforiani E, Memo M, Govoni S (2008) Pharmacogenetics and pharmagenomics, trends in normal and pathological aging studies: focus on p53. Curr Pharm Des 14, 2665-2671.
29. Zetterberg H, Wahlund LO, Blennow K (2003) Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352, 67-69.
30. Sabbagh MN (2009) Drug development for Alzheimer's disease: where are we now and where are we headed? Am J Geriatr Pharmacother 7, 167-185.
31. Uberti D, Lanni C, Carsana T, Francisconi S, Missale C, Racchi M, Govoni S, Memo M (2006) Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol Aging 27, 1193-1201.
32. Lanni C, Uberti D, Racchi M, Govoni S, Memo M(2007) Unfolded p53: a potential biomarker for Alzheimer's disease. J Alzheimers Dis 12, 93-99.
33. Uberti D, Cenini G, Olivari L, Ferrari-Toninelli G, Porrello E, Cecchi C, Pensalfini A, Liguri G, Govoni S, Racchi M, MaurizioM( 2007) Over-expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin. J Neurochem 103, 322-333.
34. Baldeiras I, Santana I, Proença MT, Garrucho MH, Pascoal R, Rodrigues A, Duro D, Oliveira CR (2008) Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis 15, 117-128.
35. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien- Baumann B, Kurz A, Minoshima S, de Leon MJ (2008) Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 49, 390-398.
36. Herholz K, Carter SF, Jones M (2007) Positron emission tomography imaging in dementia. Br J Radiol 80 Spec No 2, S160-167.
37. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H (2004) MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med 256, 205-223. (Pubitemid 39222990)
38. Modrego PJ (2006) Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res 3, 161-170.
39. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73, 294-301.
40. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73, 287-293.
41. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362.
42. Britschgi M, Wyss-Coray T (2009) Blood protein signature for the early diagnosis of Alzheimer disease. Arch Neurol 66, 161-165.
43. de la Monte SM, Sohn YK,Wands JR (1997) Correlates of p53 and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 152, 73-83.
44. Kitamura Y, Shimohama S, Kamoshima W, Matsuoka Y, Nomura Y, Taniguchi T (1997) Changes of p53 in the brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 232, 418-421.
45. Seidl R, Fang-Kircher S, Bidmon B, Cairns N, Lubec G (1999) Apoptosis-associated proteins p53 and APO-1/Fas (CD95) in brains of adult patients with down syndrome. Neurosci Lett 260, 9-12.